Showing results (411-420 of 658) with videos related to
Sort By:
Pageof 66
Journal of Neuro-Oncology|November 19, 2023
Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECTMackenzie Price, Corey Neff, Carol Kruchko, et al.Neuro-Oncology Practice|August 7, 2019
Association of genetic variants with fatigue in patients with malignant gliomaTerri S Armstrong, Elizabeth Vera, Renke Zhou, et al.Neuro-Oncology|March 8, 2011
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03Fabio M Iwamoto, Kathleen R Lamborn, John G Kuhn, et al.Cancer Research|February 17, 2017
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA RepairYanxin Lu, Jakub Kwintkiewicz, Yang Liu, et al.Acta Neuropathologica Communications|July 10, 2020
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymomaMark Raffeld, Zied Abdullaev, Svetlana D Pack, et al.Cancer Letters|December 5, 2017
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiationWinson S Ho, Saman Sizdahkhani, Shuyu Hao, et al.Neuro-Oncology|December 7, 2013
Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiationChristian L Barney, Aaron P Brown, David R Grosshans, et al.Biophysical Journal|November 15, 2020
A Novel In Vitro Device to Deliver Induced Electromagnetic Fields to Cell and Tissue CulturesRea Ravin, Teddy X Cai, Randall H Pursley, et al.Journal of Translational Medicine|February 11, 2016
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cellsTakashi Shingu, Lindsay Holmes, Verlene Henry, et al.Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Managing Cancer and Living Meaningfully Therapy Delivered as a novel remote intervention in individuals diagnosed with a Primary Central Nervous System TumorAlvina Acquaye-Mallory, Gary Rodin, Madhura Managoli, et al.Pageof 66